Metraipolis › archive › dc_9e64cf3dc0ae

IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancers — Europe PMC PMID:42167507

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42167507
DOI
10.1016/j.jhepr.2026.101899
License (as archived)
solo-consultazione
Archived
2026-11-01T13:36:42.584Z
SHA-256 of the archived text
cbb3a9a0b5b281cf1de2eaa5585885dc02f832ec424787d381b0edb42e4d07f8
Stable URL of this page
https://metraipolis.com/documento/dc_9e64cf3dc0ae

How to cite

IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancers — Europe PMC PMID:42167507 — Europe PMC (en), https://europepmc.org/article/MED/42167507 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9e64cf3dc0ae (Metraipolis archive dc_9e64cf3dc0ae, sha256 cbb3a9a0b5b281cf1de2eaa5585885dc02f832ec424787d381b0edb42e4d07f8)
BibTeX
@misc{dc9e64cf3dc0ae,
  title = {IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancers — Europe PMC PMID:42167507},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42167507},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9e64cf3dc0ae; sha256 cbb3a9a0b5b281cf1de2eaa5585885dc02f832ec424787d381b0edb42e4d07f8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42167507. Agents can read the archived copy with the MCP tool read_document.